{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T15:55:54Z","timestamp":1721404554236},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,2,12]],"date-time":"2014-02-12T00:00:00Z","timestamp":1392163200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/1471-2377-14-27","type":"journal-article","created":{"date-parts":[[2014,2,12]],"date-time":"2014-02-12T07:03:31Z","timestamp":1392188611000},"source":"Crossref","is-referenced-by-count":5,"title":["Natalizumab treatment for multiple sclerosis: Middle East and North Africa regional recommendations for patient selection and monitoring"],"prefix":"10.1186","volume":"14","author":[{"given":"Raed A","family":"Alroughani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hany M","family":"Aref","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saeed A","family":"Bohlega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurice P","family":"Dahdaleh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imed","family":"Feki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed A","family":"Al Jumah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Z","family":"Al-Kawi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salam F","family":"Koussa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamad A","family":"Sahraian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isa A","family":"Alsharoqi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bassem I","family":"Yamout","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,2,12]]},"reference":[{"key":"955_CR1","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.1007\/s00415-013-6876-4","volume":"260","author":"S Bohlega","year":"2013","unstructured":"Bohlega S, Al Tahan AR, Madani AB, Qahtani H, Rieckmann P: Multiple sclerosis in the Arabian Gulf countries: a consensus statement. J Neurol. 2013, 260: 2959-2963.","journal-title":"J Neurol"},{"key":"955_CR2","volume-title":"Mult Scler","author":"R Alroughani","year":"2013","unstructured":"Alroughani R, Ahmed SF, Behbahani R, Khan R, Thussu A, Alexander KJ, Ashkanani A, Nagarajan V, Al-Hashel J: Increasing prevalence and incidence rates of multiple sclerosis in Kuwait. Mult Scler. 2013, doi:10.1177\/1352458513504328 [ePub ahead of print]"},{"key":"955_CR3","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1177\/1352458512459291","volume":"19","author":"D Deleu","year":"2013","unstructured":"Deleu D, Mir D, Al Tabouki A, Mesraoua R, Mesraoua B, Akhtar N, Al Hail H, D\u2019souza A, Melikyan G, Imam YZ, Osman Y, Elalamy O, Sokrab T, Kamran S, Ruiz Miyares F, Ibrahim F: Prevalence, demographics and clinical characteristics of multiple sclerosis in Qatar. Mult Scler. 2013, 19: 816-819.","journal-title":"Mult Scler"},{"key":"955_CR4","doi-asserted-by":"publisher","first-page":"393","DOI":"10.3109\/00207454.2011.565893","volume":"121","author":"J Inshasi","year":"2011","unstructured":"Inshasi J, Thakre M: Prevalence of multiple sclerosis in Dubai, United Arab Emirates. Int J Neurosci. 2011, 121: 393-398.","journal-title":"Int J Neurosci"},{"key":"955_CR5","unstructured":"Natalizumab summary of product characteristics. 2011, UK: Biogen Idec Ltd, [\n                    https:\/\/www.medicines.org.uk\/emc\/medicine\/18447\/SPC\/TYSABRI+300+mg+concentrate+for+solution+for+infusion\/\n                    \n                  ]"},{"key":"955_CR6","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1056\/NEJMoa044397","volume":"354","author":"CH Polman","year":"2006","unstructured":"Polman CH, O\u2019Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW, AFFIRM Investigators: A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006, 354: 889-910.","journal-title":"N Engl J Med"},{"key":"955_CR7","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1212\/01.wnl.0000260064.77700.fd","volume":"68","author":"DH Miller","year":"2007","unstructured":"Miller DH, Soon D, Fernando KT, MacManus DG, Barker GJ, Yousry TA, Fisher E, O\u2019Connor PW, Phillips JT, Polman CH, Kappos L, Hutchinson M, Havrdova E, Lublin FD, Giovannoni G, Wajgt A, Rudick R, Lynn F, Panzara MA, Sandrock AW, AFFIRM Investigators: MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology. 2007, 68: 1390-1401.","journal-title":"Neurology"},{"key":"955_CR8","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1056\/NEJMoa044396","volume":"354","author":"RA Rudick","year":"2006","unstructured":"Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, Lublin FD, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA, Sandrock AW, SENTINEL Investigators: Natalizumab plus interferon beta-1 for relapsing multiple sclerosis. N Engl J Med. 2006, 354: 911-923.","journal-title":"N Engl J Med"},{"key":"955_CR9","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1212\/01.wnl.0000343880.13764.69","volume":"72","author":"AD Goodman","year":"2009","unstructured":"Goodman AD, Rossman H, Bar-Or A, Miller A, Miller DH, Schmierer K, Lublin F, Khan O, Bormann NM, Yang M, Panzara MA, Sandrock AW, GLANCE Investigators: GLANCE: results of a phase II, randomized, double-blind, placebo-controlled study. Neurology. 2009, 72: 806-812.","journal-title":"Neurology"},{"key":"955_CR10","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/S1474-4422(09)70021-3","volume":"8","author":"E Havrdova","year":"2009","unstructured":"Havrdova E, Galetta S, Hutchinson M, Stefoski D, Bates D, Polman CH, O\u2019Connor PW, Giovannoni G, Phillips JT, Lublin FD, Pace A, Kim R, Hyde R: Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the natalizumab safety and efficacy in relapsing-remitting multiple sclerosis (AFFIRM) study. Lancet Neurol. 2009, 8: 254-260.","journal-title":"Lancet Neurol"},{"key":"955_CR11","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1177\/1352458511399611","volume":"17","author":"JT Phillips","year":"2011","unstructured":"Phillips JT, Giovannoni G, Lublin FD, O\u2019Connor PW, Polman CH, Willoughby E, Aschenbach W, Pace A, Hyde R, Munschauer FE: Sustained improvement in expanded disability status scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis. Mult Scler. 2011, 17: 970-979.","journal-title":"Mult Scler"},{"key":"955_CR12","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.ncl.2008.03.007","volume":"26","author":"T Weber","year":"2008","unstructured":"Weber T: Progressive multifocal leukoencephalopathy. Neurol Clin. 2008, 26: 833-854.","journal-title":"Neurol Clin"},{"key":"955_CR13","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/S1474-4422(11)70149-1","volume":"10","author":"L Kappos","year":"2011","unstructured":"Kappos L, Bates D, Edan G, Eraksoy M, Garcia-Merino A, Grigoriadis N, Hartung HP, Havrdov\u00e1 E, Hillert J, Hohlfeld R, Kremenchutzky M, Lyon-Caen O, Miller A, Pozzilli C, Ravnborg M, Saida T, Sindic C, Vass K, Clifford DB, Hauser S, Major EO, O\u2019Connor PW, Weiner HL, Clanet M, Gold R, Hirsch HH, Rad\u00fc EW, S\u00f8rensen PS, King J: Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol. 2011, 10: 745-758.","journal-title":"Lancet Neurol"},{"key":"955_CR14","volume-title":"Poster P04.271, 65th AAN meeting","author":"T Dong-Si","year":"2013","unstructured":"Dong-Si T, Richman S, Bloomgren G, Wenten M, Philip J, Datta S, McIninch J, Bozic C, Ticho B, Richert N: Natalizumab-associated progressive multifocal leukoencephalopathy (PML) in multiple sclerosis patients: survival and functional outcome when asymptomatic at diagnosis. Poster P04.271, 65th AAN meeting. 2013, San Diego, CA"},{"key":"955_CR15","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/ana.22366","volume":"69","author":"CH Polman","year":"2011","unstructured":"Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O\u2019Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS: Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011, 69: 292-302.","journal-title":"Ann Neurol"},{"key":"955_CR16","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","volume":"33","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke JF: Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983, 33: 1444-1452.","journal-title":"Neurology"},{"key":"955_CR17","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/j.1600-0404.2008.01076.x","volume":"119","author":"M Vercellino","year":"2009","unstructured":"Vercellino M, Romagnolo A, Mattioda A, Masera S, Piacentino C, Merola A, Chi\u00f2 A, Mutani R, Cavalla P: Multiple sclerosis relapses: a multivariable analysis of residual disability determinants. Acta Neurol Scand. 2009, 119: 126-130.","journal-title":"Acta Neurol Scand"},{"key":"955_CR18","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1212\/01.WNL.0000096175.39831.21","volume":"61","author":"FD Lublin","year":"2003","unstructured":"Lublin FD, Baier M, Cutter G: Effect of relapses on development of residual deficit in multiple sclerosis. Neurology. 2003, 61: 1528-1532.","journal-title":"Neurology"},{"key":"955_CR19","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1093\/brain\/awq076","volume":"133","author":"E Leray","year":"2010","unstructured":"Leray E, Yaouanq J, Le Page E, Coustans M, Laplaud D, Oger J, Edan G: Evidence for a two-stage disability progression in multiple sclerosis. Brain. 2010, 133: 1900-1913.","journal-title":"Brain"},{"key":"955_CR20","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1016\/S0140-6736(98)03334-0","volume":"352","author":"PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group","year":"1998","unstructured":"PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group: Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing\/remitting multiple sclerosis. Lancet. 1998, 352: 1498-1504.","journal-title":"Lancet"},{"key":"955_CR21","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1212\/WNL.43.4.655","volume":"43","author":"The IFNB Multiple Sclerosis Study Group","year":"1993","unstructured":"The IFNB Multiple Sclerosis Study Group: Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 1993, 43: 655-661.","journal-title":"Neurology"},{"key":"955_CR22","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1212\/WNL.45.7.1268","volume":"45","author":"KP Johnson","year":"1995","unstructured":"Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB, the Copolymer 1 Multiple Sclerosis Study Group: Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. Neurology. 1995, 45: 1268-1276.","journal-title":"Neurology"},{"key":"955_CR23","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/ana.410390304","volume":"39","author":"LD Jacobs","year":"1996","unstructured":"Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Granger CV, Simon JH, Alam JJ, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer FE, Priore RL, Pullicino PM, Scherokman BJ, Whitham RH, the Multiple Sclerosis Collaborative Research Group (MSCRG): Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol. 1996, 39: 285-294.","journal-title":"Ann Neurol"},{"key":"955_CR24","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1056\/NEJMoa0909494","volume":"362","author":"L Kappos","year":"2010","unstructured":"Kappos L, Radue EW, O\u2019Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P, FREEDOMS Study Group: A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010, 362: 387-401.","journal-title":"N Engl J Med"},{"key":"955_CR25","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s00415-009-0093-1","volume":"256","author":"M Hutchinson","year":"2009","unstructured":"Hutchinson M, Kappos L, Calabresi PA, Confavreux C, Giovannoni G, Galetta SL, Havrdova E, Lublin FD, Miller DH, O\u2019Connor PW, Phillips JT, Polman CH, Radue EW, Rudick RA, Stuart WH, Wajgt A, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA, AFFIRM and SENTINEL Investigators: The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. J Neurol. 2009, 256: 405-415.","journal-title":"J Neurol"},{"key":"955_CR26","unstructured":"Fingolimod EPAR Gilenya assessment report EMA\/108602\/2011. 2011, UK: European Medicines Agency, [\n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002202\/WC500104529.pdf\n                    \n                  ]"},{"key":"955_CR27","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1007\/s00415-012-6809-7","volume":"260","author":"L Kappos","year":"2013","unstructured":"Kappos L, O\u2019Connor PW, Polman CH, Vermersch P, Wiendl H, Pace A, Zhang A, Hotermans C: Clinical effects of natalizumab on multiple sclerosis appear early in treatment course. J Neurol. 2013, 260: 1388-1395.","journal-title":"J Neurol"},{"key":"955_CR28","volume-title":"Presented at ENS","author":"L Kappos","year":"2012","unstructured":"Kappos L, Belachew S, Butzkueven H, Pellegrini F, Trojano M, Wiendl H, Zhang A, Arnold R: Presented at ENS. 2012, Prague, Czech Republic, O261"},{"key":"955_CR29","doi-asserted-by":"publisher","first-page":"e58643","DOI":"10.1371\/journal.pone.0058643","volume":"8","author":"A Svenningsson","year":"2013","unstructured":"Svenningsson A, Falk E, Celius EG, Fuchs S, Schreiber K, Berk\u00f6 S, Sun J, Penner IK, for The Tynergy Trial Investigators: Natalizumab treatment reduces fatigue in multiple sclerosis. Results from the TYNERGY Trial; a study in the real life setting. PLoS One. 2013, 8: e58643-","journal-title":"PLoS One"},{"key":"955_CR30","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1177\/1352458510394701","volume":"17","author":"C Holm\u00e9n","year":"2011","unstructured":"Holm\u00e9n C, Piehl F, Hillert J, Fogdell-Hahn A, Lundkvist M, Karlberg E, Nilsson P, Dahle C, Feltelius N, Svenningsson A, Lycke J, Olsson TA: Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis. Mult Scler. 2011, 17: 708-719.","journal-title":"Mult Scler"},{"key":"955_CR31","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/j.1468-1331.2010.03112.x","volume":"18","author":"S Belachew","year":"2011","unstructured":"Belachew S, Phan-Ba R, Bartholom\u00e9 E, Delvaux V, Hansen I, Calay P, Hafsi KE, Moonen G, Tshibanda L, Vokaer M: Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis. Eur J Neurol. 2011, 18: 240-245.","journal-title":"Eur J Neurol"},{"key":"955_CR32","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1177\/1352458512471878","volume":"19","author":"A Ghezzi","year":"2013","unstructured":"Ghezzi A, Pozzilli C, Grimaldi LM, Moiola L, Brescia-Morra V, Lugaresi A, Lus G, Rinaldi F, Rocca MA, Trojano M, Bianchi A, Comi G, Filippi M, Italian MS Study Group: Natalizumab in pediatric multiple sclerosis: results of a cohort of 55 cases. Mult Scler. 2013, 19: 1106-12. 32","journal-title":"Mult Scler"},{"key":"955_CR33","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ejpn.2012.09.004","volume":"17","author":"C Arnal-Garcia","year":"2013","unstructured":"Arnal-Garcia C, Garc\u00eda-Montero MR, M\u00e1laga I, Mill\u00e1n-Pascual J, Oliva-Nacarino P, Rami\u00f3-Torrent\u00e0 L, Oreja-Guevara C: Natalizumab use in pediatric patients with relapsing-remitting multiple sclerosis. Eur J Paediatr Neurol. 2013, 17: 50-4.","journal-title":"Eur J Paediatr Neurol"},{"key":"955_CR34","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1177\/1756285610381526","volume":"3","author":"EA Yeh","year":"2010","unstructured":"Yeh EA, Weinstock-Guttman B: Natalizumab in pediatric multiple sclerosis patients. Ther Adv Neurol Disord. 2010, 3: 293-9.","journal-title":"Ther Adv Neurol Disord"},{"key":"955_CR35","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1212\/WNL.0b013e31821e7c8a","volume":"76","author":"PW O\u2019Connor","year":"2011","unstructured":"O\u2019Connor PW, Goodman A, Kappos L, Lublin FD, Miller DH, Polman C, Rudick RA, Aschenbach W, Lucas N: Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology. 2011, 76: 1858-1865.","journal-title":"Neurology"},{"key":"955_CR36","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1056\/NEJMoa054693","volume":"354","author":"TA Yousry","year":"2006","unstructured":"Yousry TA, Major EO, Ryschkewitsch C, Fahle G, Fischer S, Hou J, Curfman B, Miszkiel K, Mueller-Lenke N, Sanchez E, Barkhof F, Radue EW, J\u00e4ger HR, Clifford DB: Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med. 2006, 354: 924-933.","journal-title":"N Engl J Med"},{"key":"955_CR37","unstructured":"Biogen Idec: Natalizumab safety update. Available at: \n                    https:\/\/medinfo.biogenidec.com\n                    \n                   (accessed May 2013)"},{"key":"955_CR38","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.jcv.2013.02.002","volume":"57","author":"P Lee","year":"2013","unstructured":"Lee P, Plavina T, Castro A, Berman M, Jaiswal D, Rivas S, Schlain B, Subramanyam M: A second-generation ELISA (STRATIFY JCV\u2122 DxSelect\u2122) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification. J Clin Virol. 2013, 57: 141-146.","journal-title":"J Clin Virol"},{"key":"955_CR39","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/ana.22128","volume":"68","author":"L Gorelik","year":"2010","unstructured":"Gorelik L, Lerner M, Bixler S, Crossman M, Schlain B, Simon K, Pace A, Cheung A, Chen LL, Berman M, Zein F, Wilson E, Yednock T, Sandrock A, Goelz SE, Subramanyam M: Anti-JC Virus Antibodies: implications for PML risk stratification. Ann Neurol. 2010, 68: 295-303.","journal-title":"Ann Neurol"},{"key":"955_CR40","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1002\/ana.23676","volume":"72","author":"TA Yousry","year":"2012","unstructured":"Yousry TA, Pelletier D, Cadavid D, Gass A, Richert ND, Radue EW, Filippi M: Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol. 2012, 72: 779-787.","journal-title":"Ann Neurol"},{"key":"955_CR41","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1212\/01.wnl.0000341766.59028.9d","volume":"72","author":"B Khatri","year":"2009","unstructured":"Khatri B, Man S, Giovannoni G, Koo AP, Lee JC, Tucky B, Lynn F, Jurgensen S, Woodworth J, Goelz S, Duda PW, Panzara MA, Ransohoff RM, Fox RJ: Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology. 2009, 72: 402-409.","journal-title":"Neurology"},{"key":"955_CR42","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1056\/NEJMoa0810257","volume":"361","author":"W Wenning","year":"2009","unstructured":"Wenning W, Haghikia A, Laubenberger M, Clifford DB, Behrens PF, Chan A, Gold R: Treatment of progressive multifocal leukoencephalopathy associated with natalizumab. N Engl J Med. 2009, 361: 1075-1080.","journal-title":"N Engl J Med"},{"key":"955_CR43","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/S1474-4422(10)70028-4","volume":"9","author":"DB Clifford","year":"2010","unstructured":"Clifford DB, De Luca A, Simpson DM, Arendt G, Giovannoni G, Nath A: Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol. 2010, 9: 438-446.","journal-title":"Lancet Neurol"},{"key":"955_CR44","volume-title":"Poster 99 presented at 28th ECTRIMS congress","author":"N Richert","year":"2012","unstructured":"Richert N, Bloomgren G, Cadavid D, Dong-Si T, Richman S, Ticho B: Imaging findings for PML in natalizumab-treated MS patients. Poster 99 presented at 28th ECTRIMS congress. 2012, Lyon, France"},{"key":"955_CR45","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1212\/WNL.0b013e318246d6d8","volume":"78","author":"NF Blair","year":"2012","unstructured":"Blair NF, Brew BJ, Halpern JP: Natalizumab-associated PML identified in the presymptomatic phase using MRI surveillance. Neurology. 2012, 78: 507-508.","journal-title":"Neurology"},{"key":"955_CR46","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1007\/s00415-012-6426-5","volume":"259","author":"I Ayzenberg","year":"2012","unstructured":"Ayzenberg I, Lukas C, Trampe N, Gold R, Hellwig K: Value of MRI as a surrogate marker for PML in natalizumab long-term therapy. J Neurol. 2012, 259: 1732-1733.","journal-title":"J Neurol"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2377-14-27.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2377-14-27\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2377-14-27","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2377-14-27.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,23]],"date-time":"2019-01-23T06:42:02Z","timestamp":1548225722000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/1471-2377-14-27"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,12]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["955"],"URL":"https:\/\/doi.org\/10.1186\/1471-2377-14-27","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,12]]},"article-number":"27"}}